| Autor: |
Rimmensberger, P, Knebjer, M, Deep, A, Bansal, M, Hoskote, A, Javouhey, E, Jourdain, G, Latten, L, McClaren, G, Morin, L, Pons-Odena, M, Ricci, Z, Singh, Y, Schlapbach, L, Scholifield, B, Terheggen, U, Tissiere, P, Tume, LN, Verbruggen, S, Brierley, J |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| ISSN: |
1529-7535 |
| Popis: |
Objective: In children Coronavirus Disease 2019 is usually mild but can develop to severe hypoxemic failure or a severe multisystem inflammatory syndrome (MIS), the latter considered to be a post-infectious syndrome, with cardiac involvement alone or together with a toxic shock like-presentation. Given the novelty of SARS-CoV-2, the causative agent of the recent COVID-19 pandemic, little is known about the pathophysiology and phenotypic expressions of this new infectious disease, nor the optimal treatment approach.\ud \ud Study selection: From inception to July 10, 2020, repeated PubMed and open Web searches have been done by the scientific section collaborative group members of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC). \ud \ud Data Extraction: There is little in the way of clinical research in children affected by COVID-19, apart from descriptive data and epidemiology.\ud \ud Data Synthesis: Even though basic treatment and organ support considerations seem not to differ much from other critical illness, such as paediatric septic shock and multiorgan failure, seen in PICUs, some specific issues must be considered when caring for children with severe COVID-19 disease. \ud \ud Conclusions: In this clinical guidance paper, we review the current clinical knowledge of COVID-19 disease in critically ill children and discuss some specific treatment concepts based mainly on expert opinion based on limited experience and the lack of any completed controlled trials in children at this time. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
